NBNilantha Bandara

Nilantha Bandara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nilantha Bandara has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 2-(4-Hydroxyphenyl)benzothiazole dicarboxylate ester TACN chelators for64Cu PET imaging in Alzheimer's disease

    by Yujue Wang, Truc T. Huynh, Nilantha Bandara, Hong-Jun Cho, Buck E. Rogers, Liviu M. Mirica

    Herein we report a new series of bifunctional chelators (BFCs) with high affinity for amyloid β aggregates, strong binding affinity towards Cu(II), and favorable lipophilicity for potential blood–brain barrier (BBB) penetration. The alkyl carboxylate ester pendant arms show high binding affinity towards Cu(II). The BFCs form stable 64Cu-radiolabeled complexes and exhibit favorable partition coefficient (log D) values of 0.75–0.95. Among the five compounds tested, 64Cu-YW-1 and 64Cu-YW-13 complexes exhibit significant staining of amyloid plaques in ex vivo autoradiography studies.


  • Open Access

    Metal-chelating benzothiazole multifunctional compounds for the modulation and 64 Cu PET imaging of Aβ aggregation

    by Yiran Huang, Hong-Jun Cho, Nilantha Bandara, Liang Sun, Diana Tran, Buck E. Rogers, Liviu M. Mirica

    A series of multifunctional compounds and their 64 Cu complexes exhibit good affinity for Aβ aggregates and can also control Aβ toxicity.


  • Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44

    by Philipp Diebolder, Cedric Mpoy, Jalen Scott, Truc T. Huynh, Ryan Fields, Dirk Spitzer, Nilantha Bandara, Buck E. Rogers

    Glycoprotein CD44 and alternative splice variants are overexpressed in many cancers and cancer stem cells. Binding of hyaluronic acid (HA) to CD44 activates cell signaling pathways, inducing cell proliferation, cell survival, and invasion. As such, CD44 is regarded an excellent target for cancer therapy when this interaction can be blocked. In this study, we developed a CD44-specific antibody fragment and evaluated it for imaging CD44-positive cancers utilizing positron emission tomography (PET). Methods: A human single-chain antibody fragment (scFv) was generated by phage display, employing the extracellular domain (ECD) of recombinant human CD44. Specificity and affinity of the scFv-CD44 were evaluated using recombinant and tumor cell-expressed CD44. Epitope mapping of the putative CD44 binding site was performed via overlapping peptide microarray. The scFv-CD44 was reformatted into a bivalent scFv-Fc-CD44, based on human IgG1-Fc (fragment crystallizable). The scFv-Fc-CD44 was radiolabeled with copper-64 (64Cu) and zirconium-89 (89Zr). The purified reagents were injected into athymic nude mice bearing CD44-positive human tumors (MDA-MB-231, breast cancer, triple negative). Biodistribution studies were performed at different time points after injection of [64Cu]Cu-NOTA-scFv-Fc-CD44 or [89Zr]Zr-DFO-scFv-Fc-CD44. PET/computerized tomography (CT) imaging was conducted with [89Zr]Zr-DFO-scFv-Fc-CD44 on days one and seven post-injection and compared to a scFv-Fc control antibody construct targeting glycophorin A (GPA). Results: Epitope mapping of the scFv binding site revealed a linear epitope within the ECD of human CD44, capable of blocking binding to native HA. Switching from a monovalent scFv to a bivalent scFv-Fc format improved its binding affinity toward native CD44 on human breast cancer cells by nearly 200-fold. In vivo biodistribution data showed the highest tumor uptake and tumor-to-blood (TTB) ratios of [89Zr]Zr-DFO-scFv-Fc-CD44 between days five and seven. PET imaging confirmed excellent tumor specificity of [89Zr]Zr-DFO-scFv-Fc-CD44 when compared to the control scFv-Fc. Conclusion: We developed a CD44-specific scFv-Fc construct that binds with nanomolar affinity to human CD44. When radiolabeled with 64Cu or 89Zr, it demonstrated specific uptake in CD44 expressing MDA-MB-231 tumors. The high tumor uptake (~56%ID/g) warrants clinical investigation of [89Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients with CD44-positive tumors.


  • 64 Cu-ATSM Positron Emission Tomography/Magnetic Resonance Imaging of Hypoxia in Human Atherosclerosis

    by Xingyu Nie, Andrew Elvington, Richard Laforest, Jie Zheng, Thomas F. Voller, Mohamed A. Zayed, Dana R. Abendschein, Nilantha Bandara, Jinbin Xu, Ran Li, et al.


  • Alteration of Cellular Reduction Potential Will Change 64Cu-ATSM Signal With or Without Hypoxia

    by John M. Floberg, Lingjue Wang, Nilantha Bandara, Ramachandran Rashmi, Cedric Mpoy, Joel R. Garbow, Buck E. Rogers, Gary J. Patti, Julie K. Schwarz

    Therapies targeting reductive/oxidative (redox) metabolism hold potential in cancers resistant to chemotherapy and radiation. A redox imaging marker would help identify cancers susceptible to redox-directed therapies. Copper(II)-diacetyl-bis(4-methylthiosemicarbazonato) (Cu-ATSM) is a PET tracer developed for hypoxia imaging that could potentially be used for this purpose. We aimed to demonstrate that Cu-ATSM signal is dependent on cellular redox state, irrespective of hypoxia. Methods: We investigated the relationship between 64Cu-ATSM signal and redox state in human cervical and colon cancer cells. We altered redox state using drug strategies and single-gene mutations in isocitrate dehydrogenases (IDH1/2). Concentrations of reducing molecules were determined by spectrophotometry and liquid chromatography–mass spectrometry and compared with 64Cu-ATSM signal in vitro. Mouse models of cervical cancer were used to evaluate the relationship between 64Cu-ATSM signal and levels of reducing molecules in vivo, as well as to evaluate the change in 64Cu-ATSM signal after redox-active drug treatment. Results: A correlation exists between baseline 64Cu-ATSM signal and cellular concentration of glutathione, nicotinamide adenine dinucleotide phosphate (NADPH), and nicotinamide adenine dinucleotide (NADH). Altering NADH and NADPH metabolism using drug strategies and IDH1 mutations resulted in significant changes in 64Cu-ATSM signal under normoxic conditions. Hypoxia likewise changed 64Cu-ATSM signal, but treatment of hypoxic cells with redox-active drugs resulted in a more dramatic change than hypoxia alone. A significant difference in NADPH was seen between cervical tumor orthotopic implants in vivo, without a corresponding difference in 64Cu-ATSM signal. After treatment with β-lapachone, there was a change in 64Cu-ATSM signal in xenograft tumors smaller than 50 mg but not in larger tumors. Conclusion:64Cu-ATSM signal reflects redox state, and altering redox state impacts 64Cu-ATSM metabolism. Our animal data suggest there are other modulating factors in vivo. These findings have implications for the use of 64Cu-ATSM as a predictive marker for redox therapies, though further in vivo work is needed.


  • CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia

    by Barbara Muz, Nilantha Bandara, Cedric Mpoy, Jennifer Sun, Kinan Alhallak, Feda Azab, Buck E. Rogers, Abdel Kareem Azab

    Objective: Waldenström Macroglobulinemia (WM) is a rare B-cell malignancy characterized by secretion of immunoglobulin M and cancer infiltration in the bone marrow. Chemokine receptor such as CXCR4 and hypoxic condition in the bone marrow play crucial roles in cancer cell trafficking, homing, adhesion, proliferation, survival, and drug resistance. Herein, we aimed to use CXCR4 as a potential biomarker to detect hypoxic-metastatic WM cells in the bone marrow and in the circulation by using CXCR4-detecting radiopharmaceutical. Methods: We radiolabeled a CXCR4-inhibitor (AMD3100) with 64Cu and tested its binding to WM cells with different levels of CXCR4 expression using gamma counter in vitro. The accumulation of this radiopharmaceutical tracer was tested in vivo in subcutaneous and intratibial models using PET/CT scan. In addition, PBMCs spiked with different amounts of WM cells ex vivo were detected using gamma counting. Results: In vitro, 64Cu-AMD3100 binding to WM cell lines demonstrated a direct correlation with the level of CXCR4 expression, which was increased in cells cultured in hypoxia with elevated levels of CXCR4, and decreased in cells with CXCR4 and HIF-1α knockout. Moreover, 64Cu-AMD3100 detected localized and circulating CXCR4high WM cells with high metastatic potential. Conclusions: In conclusion, we developed a molecularly targeted system, 64Cu-AMD3100, which binds to CXCR4 and specifically detects WM cells with hypoxic phenotype and metastatic potential in the subcutaneous and intratibial models. These preliminary findings using CXCR4-detecting PET radiopharmaceutical tracer indicate a potential technology to predict high-risk patients for the progression to WM due to metastatic potential.


  • Open Access

    Aerosol-synthesized siliceous nanoparticles: impact of morphology and functionalization on biodistribution

    by Philipp Diebolder, Miguel Vazquez-Pufleau, Nilantha Bandara, Cedric Mpoy, Ramesh Raliya, Elijah Thimsen, Pratim Biswas, Buck E Rogers

    Aerosol-synthesized siliceous nanoparticles: impact of morphology and functionalization on biodistribution Philipp Diebolder,1 Miguel Vazquez-Pufleau,2 Nilantha Bandara,1 Cedric Mpoy,1 Ramesh Raliya,2 Elijah Thimsen,2 Pratim Biswas,2 Buck E Rogers1 1Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA; 2Department of Energy, Environmental and Chemical Engineering, Washington University in St Louis, St Louis, MO, USA Introduction: Siliceous nanoparticles (NPs) have been extensively studied in nanomedicine due to their high biocompatibility and immense biomedical potential. Although numerous technologies have been developed, the synthesis of siliceous NPs for biomedical applications mainly relies on a few core technologies predominantly intended to produce spherical-shaped NPs. Methods: In this context, the impact of different morphologies of siliceous NPs on biodistribution in vivo is limited. In the present study, we developed a novel technique based on an aerosol silane reactor to produce sintered silicon NPs of similar size but different surface areas due to distinct spherical subunits. Silica-converted particles were functionalized for radiolabeling with copper-64 (64Cu) to systematically analyze their behavior in the passive targeting of A431 tumor xenografts in mice after intravenous injection.Results: While low nonspecific uptake was observed in most organs, the majority of particles were accumulated in the liver, spleen, and lung. Depending on the morphologies and functionalization, significant differences in the uptake profiles of the particles were observed. In terms of tumor uptake, spherical shapes with lower surface areas showed the highest accumulation and tumor-to-blood ratios of all investigated particles.Conclusion: This study highlights the importance of shape and fuctionalization of siliceous NPs on organ and tumor accumulation as significant factors for biomedical applications. Keywords: silicon, silica, human tumor xenograft, PEGylation, 64Cu


  • Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer

    by Nilantha Bandara, Tamila J. Stott Reynolds, Rebecca Schehr, Rajendra P. Bandari, Philipp J. Diebolder, Stephanie Krieger, Jingli Xu, Yubin Miao, Buck E. Rogers, Charles J. Smith


  • Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent

    by Nilantha Bandara, Orit Jacobson, Cedric Mpoy, Xiaoyuan Chen, Buck Edward Rogers

    Development of somastatin (SS) peptide analogs for detection and treatment of neuroendocrine tumors has been successful with the recent FDA approval of 68Ga-DOTA-TATE and 177Lu-DOTA-TATE. The structure of these peptide constructs contains the peptide binding motif that binds to the receptor with high affinity, a chelator to complex the radioactive metal, and a linker between the peptide and chelator. However, these constructs suffer from rapid blood clearance, which limit their tumor uptake. In this study, this design has been further improved by incorporating a modification to control the in vivo pharmacokinetics. Adding a truncated Evans Blue (EB) dye molecule into the construct provides a prolonged half-life in blood due to its low micromolar affinity to albumin. We compared 177Lu-DOTA-TATE to the modified 177Lu Evans Blue compound (177Lu-DMEB-TATE), in vitro and in vivo in mice bearing A427-7 xenografts. The tumor uptake of 177Lu-DMEB-TATE was significantly greater than the uptake of 177Lu-DOTA-TATE in biodistribution and SPECT imaging studies. The therapeutic effect of 177Lu-DMEB-TATE construct was superior to the 177Lu-DOTA-TATE construct at the doses evaluated.


  • Open Access

    Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer’s Disease

    by Nilantha Bandara, Anuj K. Sharma, Stephanie Krieger, Jason W. Schultz, Byung Hee Han, Buck E. Rogers, Liviu M. Mirica

    Positron emission tomography (PET) imaging agents that detect amyloid plaques containing amyloid beta (Aβ) peptide aggregates in the brain of Alzheimer’s disease (AD) patients have been successfully developed and recently approved by the FDA for clinical use. However, the short half-lives of the currently used radionuclides 11C (20.4 min) and 18F (109.8 min) may limit the widespread use of these imaging agents. Therefore, we have begun to evaluate novel AD diagnostic agents that can be radiolabeled with 64Cu, a radionuclide with a half-life of 12.7 h, ideal for PET imaging. Described herein are a series of bifunctional chelators (BFCs), L1–L5, that were designed to tightly bind 64Cu and shown to interact with Aβ aggregates both in vitro and in transgenic AD mouse brain sections. Importantly, biodistribution studies show that these compounds exhibit promising brain uptake and rapid clearance in wild-type mice, and initial microPET imaging studies of transgenic AD mice suggest that these compounds could serve as lead compounds for the development of improved diagnostic agents for AD.